Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Entrectinib

FDA-approved product (capsule, oral), marketed as Rozlytrek.

Registered studies
46
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Entrectinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli50.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae39.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

46registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Entrectinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-10.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-11.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-10.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Entrectinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver Mutations

    NCT07829744 · start 2026-09-20

    Registered record
    Registry ID
    NCT07829744
    Conditions
    Lung Cancer (NSCLC)
    Interventions
    Surgical Resection
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-09-20
    Completion
    2030-06-30
    Enrolment
    190

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer (NSCLC)
    InterventionSurgical Resection
    PhasePhase 2
    Registry statusNot yet recruiting

  • Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

    NCT06528691 · start 2026-05-01

    Registered record
    Registry ID
    NCT06528691
    Conditions
    High Grade Glioma; CNS Tumor
    Interventions
    Entrectinib; Cyclophosphamide; Etoposide; Carboplatin; G-CSF; Pegfilgrastim; Surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-05-01
    Completion
    2032-11
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigh Grade Glioma; CNS Tumor
    InterventionEntrectinib; Cyclophosphamide; Etoposide; Carboplatin +3 more
    PhasePhase 2
    Registry statusRecruiting

  • DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.

    NCT05770544 · start 2025-11-30

    Registered record
    Registry ID
    NCT05770544
    Conditions
    Haematological Malignancy; Malignancy; Malignant Neoplasm; Lymphoproliferative Disorders; Neoplasms by Histologic Type; Neoplasms by Site; Cancer; Brain Neoplasms; Melanoma; Glioma; Solid Tumour
    Interventions
    Entrectinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2025-11-30
    Completion
    2029-10
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHaematological Malignancy; Malignancy; Malignant Neoplasm; Lymphoproliferative Disorders +7 more
    InterventionEntrectinib
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression

    NCT07199010 · start 2025-10

    Registered record
    Registry ID
    NCT07199010
    Conditions
    Non-small Lung Cancer
    Interventions
    Taletrectinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2025-10
    Completion
    2027-12
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Lung Cancer
    InterventionTaletrectinib
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Study on the Mechanism of Acquired Resistance of Entrectinib

    NCT07199959 · start 2025-01-15

    Registered record
    Registry ID
    NCT07199959
    Conditions
    ROS1 Fusion Positive; Non Small Cell Lung Cancer
    Interventions
    venipuncyure; Entrectinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-01-15
    Completion
    2026-12-01
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionROS1 Fusion Positive; Non Small Cell Lung Cancer
    Interventionvenipuncyure; Entrectinib
    PhaseNot recorded
    Registry statusRecruiting

  • Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

    NCT06692491 · start 2025-01-01

    Registered record
    Registry ID
    NCT06692491
    Conditions
    Rare Tumour
    Interventions
    Albumin-Bound Paclitaxel; Epirubicin; Gemcitabine; Vinorelbine; Cisplatin; Irinotecan; Fluorouracil; Nivolumab; Pembrolizumab; Durvalumab; Atezolizumab; Sintilimab; Tislelizumab; Camrelizumab; Toripalimab; Serplulimab; Adebrelimab; Envafolimab; Osimertinib; Alectinib; Vemurafenib; Pamiparib; Pyrotinib; Imatinib; Palbociclib; Savolitinib; Entrectinib; Other
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-01-01
    Completion
    2029-12-31
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRare Tumour
    InterventionAlbumin-Bound Paclitaxel; Epirubicin; Gemcitabine; Vinorelbine +24 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC

    NCT06694129 · start 2024-12-01

    Registered record
    Registry ID
    NCT06694129
    Conditions
    Non-Small Cell Lung Cancer; ROS1 Gene Rearrangement; Resistance; Targeted Therapy
    Interventions
    Entrectinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2024-12-01
    Completion
    2027-12-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer; ROS1 Gene Rearrangement; Resistance; Targeted Therapy
    InterventionEntrectinib
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

    NCT06145308 · start 2023-08-15

    Registered record
    Registry ID
    NCT06145308
    Conditions
    Salivary Gland Carcinoma; Precision Therapy
    Interventions
    Cohort 1 (HER2-positive, RC48-ADC); Cohort 2 (NTRK-fusion or NTRK-mutant); Cohort 3 (AR-positive, leuprolide + bicalutamide + abiraterone); TROP2 ADC; TKI; Albumin-paclitaxel + platinum; Albumin-paclitaxel + carboplatin + apatinib + camrelizumab; albumin-bound paclitaxel+trastuzumab+pyrotinib; HER2,trastuzumab deruxtecan± pertuzumab; AR,AR antagonist ++ goserelin + pertuzumab + trastuzumab; AR,AR antagonist +goserelin +docetaxel; ivonescimab + investigator-choice platinum doublet+; iparomlimab + tuvonralimab; cadonilimab; CDK4/6 inhibitor+AI or fulvestrant; alpelisib+fulvestrant; PARP inhibitor; enfortumab vedotin; HER2, pyrotinib + pertuzumab/trastuzumab; vebecotutamab ±lenvatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-08-15
    Completion
    2028-07-10
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSalivary Gland Carcinoma; Precision Therapy
    InterventionCohort 1 (HER2-positive, RC48-ADC); Cohort 2 (NTRK-fusion or NTRK-mutant); Cohort 3 (AR-positive, leuprolide + bicalutamide + abiraterone); TROP2 ADC +16 more
    PhasePhase 2
    Registry statusRecruiting

  • A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.

    NCT05834348 · start 2023-06-23

    Registered record
    Registry ID
    NCT05834348
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    lorlatinib; crizotinib; brigatinib; ceritinib; alectinib; atezolizumab; bevacizumab; paclitaxel; carboplatin; docetaxel; erlotinib; gefitinib; afatinib; dacomitinib; osimertinib; pembrolizumab; nivolumab; entrectinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-06-23
    Completion
    2024-01-23
    Enrolment
    5,279

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    Interventionlorlatinib; crizotinib; brigatinib; ceritinib +14 more
    PhaseNot recorded
    Registry statusCompleted

  • A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

    NCT05862285 · start 2023-06-01

    Registered record
    Registry ID
    NCT05862285
    Conditions
    Cancer
    Interventions
    Ipatasertib; Tiragolumab; Atezolizumab; Tiragolumab and Atezolizumab; Bevacizumab; Entrectinib; Inavolisib; Divarasib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-06-01
    Completion
    2033-03-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer
    InterventionIpatasertib; Tiragolumab; Atezolizumab; Tiragolumab and Atezolizumab +4 more
    PhasePhase 3
    Registry statusRecruiting

  • DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

    NCT05722886 · start 2023-03-01

    Registered record
    Registry ID
    NCT05722886
    Conditions
    Haematological Malignancy; Solid Tumour
    Interventions
    Alectinib; Atezolizumab; Entrectinib; Trastuzumab in combination with pertuzumab; Vemurafenib in combination with cobimetinib; Capmatinib; Dabrafenib in combination with trametinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2023-03-01
    Completion
    2029-10
    Enrolment
    825

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHaematological Malignancy; Solid Tumour
    InterventionAlectinib; Atezolizumab; Entrectinib; Trastuzumab in combination with pertuzumab +3 more
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • SMMART Adaptive Clinical Treatment (ACT) Trial

    NCT05238831 · start 2023-01-30

    Registered record
    Registry ID
    NCT05238831
    Conditions
    Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8
    Interventions
    Alectinib; Alpelisib; Anastrozole; Atezolizumab; Bevacizumab; Biopsy; Biospecimen Collection; Capecitabine; Carboplatin; Cobimetinib; Entrectinib; Eribulin; Fulvestrant; Hyaluronidase-zzxf/Pertuzumab/Trastuzumab; Irinotecan; Letrozole; Nab-paclitaxel; Niraparib; Olaparib; Paclitaxel; Palbociclib; Pertuzumab; Quality-of-Life Assessment; Trastuzumab; Trastuzumab Emtansine; Vemurafenib; Vinorelbine; Vismodegib
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Withdrawn
    Start
    2023-01-30
    Completion
    2026-05-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma +13 more
    InterventionAlectinib; Alpelisib; Anastrozole; Atezolizumab +24 more
    PhaseEarly phase 1
    Registry statusWithdrawn

  • A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)

    NCT05170204 · start 2022-11-01

    Registered record
    Registry ID
    NCT05170204
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    Alectinib; Entrectinib; Durvalumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2022-11-01
    Completion
    2030-06-16
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionAlectinib; Entrectinib; Durvalumab
    PhasePhase 3
    Registry statusActive not recruiting

  • Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia

    NCT05396859 · start 2022-10-28

    Registered record
    Registry ID
    NCT05396859
    Conditions
    Acute Myeloid Leukemia; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia
    Interventions
    Decitabine and Cedazuridine; Entrectinib; Laboratory Biomarker Analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2022-10-28
    Completion
    2026-12-31
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia
    InterventionDecitabine and Cedazuridine; Entrectinib; Laboratory Biomarker Analysis
    PhasePhase 1
    Registry statusActive not recruiting

  • KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II

    NCT05525858 · start 2022-09-28

    Registered record
    Registry ID
    NCT05525858
    Conditions
    Solid Tumor; Advanced Solid Tumor; Metastatic Cancer
    Interventions
    Alectinib; Atezolizumab; Erlotinib; Trastuzumab + Pertuzumab; Trastuzumab emtansine; Vemurafenib; Bevacizumab + Erlotinib; Entrectinib; Pralsetinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2022-09-28
    Completion
    2027-03
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumor; Advanced Solid Tumor; Metastatic Cancer
    InterventionAlectinib; Atezolizumab; Erlotinib; Trastuzumab + Pertuzumab +5 more
    PhaseNot recorded
    Registry statusRecruiting